Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics ... expedite the process by 6-18 months and ...

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal ... expedite the process by 6 ...

US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global rights ... how we may use, process and share your ...

At the recent JP Morgan Healthcare Conference 2025, WuXi Biologics’ CEO Chris Chen said the company continues to sign foreign clients and investing in the US, despite political headwinds related to ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...